Mirum Pharmaceuticals, Inc. 8-K

What Happened

• Mirum Pharmaceuticals, Inc. (MIRM) announced in an 8‑K that it completed the previously announced acquisition of Bluejay Therapeutics, Inc. on January 23, 2026 pursuant to a December 6, 2025 merger agreement. The transaction closed through a two-step merger process that resulted in Bluejay becoming a wholly owned subsidiary of Mirum.

Key Details

• Mirum acquired Bluejay’s net cash of approximately $56.6 million at closing.
• Upfront Consideration: Mirum paid or will pay up to $280.8 million in cash and 4,673,597 shares of Mirum common stock (subject to delivery conditions and tax deductions).
• Holdback Consideration: Mirum will pay up to $25.8 million in cash and 522,375 shares of Mirum common stock (subject to conditions and holdbacks).
• Milestones: Mirum will make additional cash milestone payments of up to $200 million tied to net sales milestones.
• Related parties: Entities affiliated with Frazier Life Sciences IX, L.P. (associated with a Mirum director and a >5% beneficial owner) are holders of Bluejay securities and received their pro rata portion of the consideration and remain entitled to the remainder per the merger terms.
• Financing/closings: Immediately after the merger Mirum closed two previously announced private placements (subscription agreements dated Dec 7 and Dec 18, 2025). As of Jan 23, 2026, Mirum had 59,879,958 shares of common stock issued and outstanding.
• The full Merger Agreement is filed as an exhibit to the 8‑K for details and conditions.

Why It Matters

• The acquisition brings Bluejay’s assets and about $56.6M in net cash onto Mirum’s balance sheet and adds contingent future obligations (upfront, holdback and milestone payments) that could total significant cash and equity issuance if milestones are met.
• Investors should note the size and structure of the deal (cash plus shares and milestone-based payments), the immediate increase in outstanding shares activity following the private placements, and the involvement of a >5% shareholder group tied to a board member—each of which can affect dilution, cash needs, and governance considerations.